Rutgers researchers find fat gene

March 20, 2006

Rutgers researchers have identified a gene - and the molecular function of its protein product - that provides an important clue to further understanding obesity and may point the way to new drugs to control fat metabolism.

The scientists found that the human protein known as lipin is a key fat-regulating enzyme. "Lipin activity may be an important pharmaceutical target for the control of body fat in humans, treating conditions that range from obesity to the loss of fat beneath the skin, as seen in HIV patients, " said George M. Carman, a professor in Rutgers' department of food science.

In a paper published online by the Journal of Biological Chemistry (print version, April 7), Carman and his research team at Rutgers' Cook College describe their scientific detective work, moving from clue to clue in a series of logical connections to reach their discoveries.

Previous studies with mice showed that a lack of lipin causes a loss of body fat, whereas an excess of lipin promotes extra body fat. So researchers knew that lipin was involved in fat metabolism; they just didn't know how.

The Carman team's first revelation came with the discovery that lipin is an enzyme (phosphatidic acid phosphatase or PAP), a protein catalyst that is required for the formation of fats - triglycerides, specifically.

The breakthrough for Carman's group grew out of work with ordinary baker's yeast; a simple single cell organism. "We isolated the PAP enzyme from yeast that corresponds in form to lipin in mammals and showed that yeast cells lacking the enzyme exhibited a 90 percent reduction in the yeast's version of fat loss," Carman said.

The group worked out the sequence of the amino acids that make up the PAP enzyme, allowing them to backtrack along the path to its origin - the gene that coded it - linking the enzyme to the yeast gene PAH1 that made it. Carman and his group went on to confirm the link by introducing the yeast gene into bacteria, with similar results.

The researchers showed that the enzyme encoded by the PAH1 gene looks and acts very much like the lipin found in mammals. The yeast PAP enzyme shares a high resemblance to the lipin protein in mammals so they logically deduced the link between PAP enzyme function and lipin.

"These findings are of major importance to the AIDS community as well as to those concerned with the obesity epidemic," said Jean Chin, a program director at the National Institute of General Medical Sciences (NIGMS), the part of the National Institutes of Health that funded the research. Carman's research is also supported by the New Jersey Agricultural Experiment Station.

Obesity in the United States has risen at an epidemic rate during the past 20 years, a condition affecting about one-third of American adults, according to the Centers for Disease Control and Prevention. One of the national health objectives for the year 2010 is to reduce the prevalence of obesity among adults to less than 15 percent.
-end-


Rutgers University

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.